Literature DB >> 12732181

The t(8;21) fusion protein contacts co-repressors and histone deacetylases to repress the transcription of the p14ARF tumor suppressor.

Scott W Hiebert1, Edward F Reed-Inderbitzin, Joseph Amann, Brenda Irvin, Kristie Durst, Bryan Linggi.   

Abstract

The t(8;21) is one of the most frequent chromosomal translocations associated with acute leukemia. The translocation fuses the DNA binding domain of AML1 to nearly all of the ETO co-repressor. ETO associates with the mSin3 and N-CoR co-repressors as well as histone deacetylases 1, 2, and 3. Although this is one of the most frequent chromosomal translocations in acute leukemia, accounting for 10-15% of the cases of acute myeloid leukemia (AML), the direct targets for transcriptional regulation that stimulate leukemogenesis are unknown. We found that AML1-ETO repressed the promoter of p14(ARF) tumor suppressor in transient transfection assays and reduced endogenous levels of p14(ARF) expression in multiple cell types. Chromatin immunoprecipitation assays demonstrated that AML1-ETO bound to the p14(ARF) promoter. In acute myeloid leukemia samples containing the t(8;21), levels of p14(ARF) mRNA were markedly lower when compared to other acute myeloid leukemias. Therefore, p14(ARF) is a direct transcriptional target of AML1-ETO.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12732181     DOI: 10.1016/s1079-9796(03)00021-4

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  6 in total

1.  Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.

Authors:  Stephen M Wiesner; Jennifer L Geurts; Miechaleen D Diers; Rachel J Bergerson; Diane E Hasz; Kelly J Morgan; David A Largaespada
Journal:  Am J Hematol       Date:  2011-07       Impact factor: 10.047

2.  Human DMTF1β antagonizes DMTF1α regulation of the p14(ARF) tumor suppressor and promotes cellular proliferation.

Authors:  Mario P Tschan; Elena A Federzoni; Aladin Haimovici; Christian Britschgi; Bettina A Moser; Jing Jin; Venkateshwar A Reddy; Dennis A Sheeter; Kimberlee M Fischer; Peiqing Sun; Bruce E Torbett
Journal:  Biochim Biophys Acta       Date:  2015-07-15

Review 3.  Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective.

Authors:  Yoshihiro Hayashi; Yuka Harada; Hironori Harada
Journal:  Leukemia       Date:  2022-03-30       Impact factor: 11.528

4.  p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death.

Authors:  Ondrej Krejci; Mark Wunderlich; Hartmut Geiger; Fu-Sheng Chou; David Schleimer; Michael Jansen; Paul R Andreassen; James C Mulloy
Journal:  Blood       Date:  2007-11-01       Impact factor: 22.113

5.  Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network.

Authors:  Sayyed K Zaidi; Christopher R Dowdy; Andre J van Wijnen; Jane B Lian; Azra Raza; Janet L Stein; Carlo M Croce; Gary S Stein
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

Review 6.  The evolving landscape in the therapy of acute myeloid leukemia.

Authors:  Grace L Peloquin; Yi-Bin Chen; Amir T Fathi
Journal:  Protein Cell       Date:  2013-08-27       Impact factor: 14.870

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.